1. Home
  2. AVXL vs SUPV Comparison

AVXL vs SUPV Comparison

Compare AVXL & SUPV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anavex Life Sciences Corp.

AVXL

Anavex Life Sciences Corp.

HOLD

Current Price

$4.37

Market Cap

397.6M

Sector

Health Care

ML Signal

HOLD

Logo Grupo Supervielle S.A. each Representing five Class B shares

SUPV

Grupo Supervielle S.A. each Representing five Class B shares

HOLD

Current Price

$11.06

Market Cap

450.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
AVXL
SUPV
Founded
2004
1887
Country
United States
Argentina
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Commercial Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
397.6M
450.9M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
AVXL
SUPV
Price
$4.37
$11.06
Analyst Decision
Strong Buy
Buy
Analyst Count
3
4
Target Price
$22.00
$14.67
AVG Volume (30 Days)
4.6M
1.7M
Earning Date
11-25-2025
11-25-2025
Dividend Yield
N/A
1.70%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$467,987,272.00
Revenue This Year
N/A
$20.63
Revenue Next Year
N/A
$22.47
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.86
$4.54
52 Week High
$14.44
$19.75

Technical Indicators

Market Signals
Indicator
AVXL
SUPV
Relative Strength Index (RSI) 40.02 54.67
Support Level $3.62 $10.75
Resistance Level $4.84 $12.13
Average True Range (ATR) 0.42 0.80
MACD 0.23 -0.08
Stochastic Oscillator 74.53 61.79

Price Performance

Historical Comparison
AVXL
SUPV

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

About SUPV Grupo Supervielle S.A. each Representing five Class B shares

Grupo Supervielle SA offers financial products & services. The company's segments include Personal and Business Banking, Corporate Banking, Bank Treasury, Consumer Finance, Insurance, and Asset Management and other services. The company provides services to individuals, small businesses, middle-market companies, and large corporates in Argentina. The company also offers mutual fund services.

Share on Social Networks: